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Abstract 
 
Background 
A third of world’s filariasis cases occur in India. As a result 
Mass Drug Administration (MDA) was commenced in 1997 
with the aim of eliminating this disease by 2015. However 
the coverage of MDA was not satisfactory. The underlying 
reasons for the poor coverage need to be identified. This 
study was conducted to assess the awareness of health 
personnel of lymphatic filariasis and the MDA programme. 
 
Method   
This cross-sectional study was conducted in Kundapura 
taluk of Karnataka state in India during the 6
th round of the 
MDA which was held between December 11 to 13, 2009.  
78 health personnel who were posted for drug distribution 
were selected by convenience sampling. After obtaining 
informed consent health personnel were interviewed 
individually using a semi-structured questionnaire. 
Performance of health personnel was assessed according to 
points scored for their responses. 
 
Results 
The  mean  age  of  all  participants  were  22.7±  8.9  years, 
74(94.1%)  were  females  and  58(74.4%)  were  nursing 
students. Only 17 (21.8%) participants had prior experience 
before  taking  part  in  this  round  of  MDA.  Only  4  (5.1%) 
participants  achieved  good  scores  while  45  (57.7%)  got 
average  scores.  Performance  scores  were  significantly 
better  among  paramedical  workers  (P<0.025)  and 
participants  with  at  least  4  years  of  experience  in  MDA 
(P<0.004). 
10 (12.8%) participants held the misconception that MDA 
should not be given to patients with DM (diabetes mellitus) 
and 7 (9.0%) felt that it should not be given to patients with 
hypertension or elderly people. This was seen significantly 
more (P<0.001) among non medical workers compared to 
others. 
 
Conclusion 
Very  few  participants  in  this  study  attained  good 
performance scores regarding their knowledge of lymphatic 
filariasis  and  the  MDA  programme.  Performance  scores 
were  better  among  paramedical  workers  compared  to 
others. However misconceptions about contraindications to 
MDA  were  seen  in  all  participants  and  this  must  be 
addressed by future training. 
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Background 
The  World  Health  Organization  (WHO)  estimates  that 
Lymphatic Filariasis (LF), which is the second most common 
vector borne parasitic disease after malaria, affects around 
120 million people worldwide with 1 billion at risk.
[1] One 
third of the world’s infected people live in India, of which 
approximately  21  million  people  have  symptomatic 
filariasis.
[1,2] 
The disease may result in no clinical symptoms through to 
both acute and chronic manifestations such as lymphangitis, 
lymphadenitis, elephantiasis of genitals, legs and arms. 
Due to its ability to cause long term disability and suffering 
with  consequent  economic  and  social  implication,  this 
disease  has  acquired  enough  attention  for  the  WHO 
Assembly  to  call  for  its  elimination  by  use  of  mass  drug 
administration (MDA). In India, the MDA programme was 
started in 1997 with the aim of eliminating the disease by 
2015.  MDA  coverage  of  80%  for  five  years  is  deemed 
necessary  for  elimination;  however  the  coverage  to  date 
has been only 40-60%.
 [3]  
Corresponding Author: 
Dr. Nitin Joseph, MD (Community Medicine), 
Assistant  Professor,  Department  of 
Community  Medicine,  Kasturba  Medical 
College, Manipal University, Light House Hill 
Road,  Mangalore  575001,  India. 
drnitinjoseph@gmail.com 
  Australasian Medical Journal AMJ 2011, 4, 2, 87-93. 
 
 
              88
Even with adequate coverage, poor compliance may reduce 
the efficacy of the programme.
  [4] A recent study in south 
India reported that only 30.5% study participants actually 
consumed  the  drugs  distributed  under  the  MDA 
programme.    Fear,
  illness  and  misconceptions  were  the 
commonest  reasons  for  non-compliance  stated  by  non-
consumers.
 [4] From this it is obvious that several reasons for 
non-consumption  are  rectifiable  provided  that  the  drug 
distributors play an active role in educating people about 
the importance of the MDA programme.  
The MDA programme is demanding in terms of manpower, 
funds and logistics and the very purpose of it have not been 
fulfilled  so  far.  Hence  reasons  for  low  coverage  and 
consumption rate must be identified so that they can be 
corrected and the original targets achieved.  
Several studies have reported on community perception of 
filariasis  and  MDA.  However,  studies  that  investigate  the 
awareness  of  the  personnel  who  deliver  tablets  to  the 
general population are very limited. However, as discussed 
above, it is these individuals that can markedly affect the 
quality of the programme. Information from  such studies 
can  be  used  to  improve  the  training  of  these  drug 
distributors.  Another  study  done  in  South  India  reported 
unsatisfactory  awareness  about  MDA  among  paramedical 
workers. The questionnaire used in the same study was not 
very  comprehensive.
  (5)  Taking  into  consideration  these 
aspects, this study was conducted to assess the awareness 
of health personnel about lymphatic filariasis and the MDA 
programme. 
 
Method 
This  cross-sectional  study  was  conducted  in  the  Udupi 
district of Karnataka state in India during the 6
th round of 
MDA held between December 11 to 13, 2009. Institutional 
ethical committee approval was obtained before conducting 
this study. One of the three talukas (subdistricts) of Udupi 
district namely Kundapura was randomly selected for the 
study. Using the definition of an “average” awareness level 
about the MDA programme as 70% from a previous study,
(5) 
the sample size calculated for 95% confidence limits at 85% 
power was 77 participants. Out of the 180 workers posted 
for MDA activity in this taluka for the current round, 78 of 
them  were  chosen  for  enrolment  onto  the  study  by 
convenience sampling. As the MDA round was in progress 
during  this  study,  the  investigators  approached  any  drug 
distributor in the field as and when they came across them. 
Each participant, after giving verbal informed consent, was 
interviewed  individually  using  a  semi-structured 
questionnaire.  Questions  asked  included  those  about  the 
causative agent, mode of transmission, clinical features and 
laboratory diagnosis of filariasis. Questions relating to the 
MDA programme included those about dosages of various 
tablets, drug side effects, contraindications, purpose of the 
MDA,  attitudes  regarding  the  usefulness  of  MDA  to 
eliminate  filariasis  and  the  responses  of  people  after 
receiving the tablets. There were a total of 25 questions. 
Answers were scored between 1 and 7 by the investigators 
depending  on  the  importance  of  the  question  for  the 
success of the programme. All the points achieved in each 
questionnaire were totalled out of a maximum of 100 and 
the awareness level with respect to filariasis and the MDA 
programme was categorized into poor (<61), satisfactory or 
average (61 to 84) and good (>84). Categories were defined 
on the basis of the total possible scores for must know and 
nice-to-know questions. 
The  cut-off  value  for  points  below  which  performance  is 
poor was based on the cumulative points allocated to must 
know  questions  in  the  questionnaire.  The  must  know 
questions  were  names  of  the  two  drugs  delivered  under 
MDA,  their  strength,  dosages  in  various  age  groups,  side 
effects,  contraindications    and  purpose  of  giving  these 
drugs.  Similarly  the  cut-off  value  for  satisfactory 
performance was based on the cumulative points for nice to 
know questions made less from the maximum score of 100 
in the questionnaire. Details of scoring pattern are detailed 
along with the questionnaire in the appendix. 
All  the  data  collected  were  stored  and  analyzed  using 
version  11.5  of  the  Statistical  Package  for  Social  Sciences 
software  package  (SPSS  Inc.,  Chicago,IL).  Chi-square  was 
used  for  testing  statistical  significance  and  P  value  <0.05 
was considered as significant. 
 
Results  
Health personnel play a vital role in distribution of drugs to 
households. Their efficiency thus determines the success of 
MDA programme.  
Of the total 78 study participants, 74 (94.1%) were females 
and  4(5.9%)  were  males.  Mean  age  of  participants  were 
22.7± 8.9 years. 
 
Table 1. Association between performance of participants 
and their occupation and numbers of years in MDA. 
Occupation  Poor 
n(%) 
Average 
n(%) 
Good 
n(%) 
Total n(%) 
Students  25 
(43.1) 
32 (55.2)  1 (1.7)  58(100) 
Para medical 
workers
† 
2 
(13.3) 
10 (66.7)  3 (20)  15(100) 
Non medical 
workers
¶ 
2 (40)  3 (60)  0   5(100) 
      χ2  = 
11.2,DF=4,P=0.025 
Years  of 
experience 
in MDA 
       
Nil   27(44
.3) 
33(54.1)  1(1.6)  61(100) 
1 to 3 years  2(20)  7(70)  1(10.0)  10(100) 
4 to 6 years  0  5(71.4)  2(28.6)  7(100) 
Total  29(37
.2) 
45(57.7)  4(5.1)  78(100) 
      χ2=11.046,  DF=2, 
P=0.004  Australasian Medical Journal AMJ 2011, 4, 2, 87-93. 
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†Health  Workers,  Anganwadi  workers,  Laboratory 
technician, Staff nurse 
¶Non medical workers: Teachers, NSS volunteers 
 
Occupational distribution showed 58 (74.4%) participants to 
be  nursing  students,  8  (10.3%)  were  health  workers,  4 
(5.1%)  were  anganwadi  workers  (employed  under 
Integrated  Child  Development  Services,  Government  of 
India),  3  (3.8%)  were  NSS  (National  Service  Scheme) 
activists, 2 (2.6%) were teachers, 2 (2.6%) were laboratory 
technicians and 1 (1.3%) was a staff nurse. 
As  regards  the  participants’  experience  of  the  MDA,  10 
(12.8%) had 1 to 3 years experience and only 7 (9.0%) had 4 
to 6 years experience before taking part in this round of the 
programme. 
The mean score of all participants was 60.5±18.7 points. The 
performance score showed that 4 (5.1%) participants were 
found  to  have  a  “good”  awareness  level,  45  (57.7%)  an 
“average”  awareness  level  and  29  (37.2%)  a  “poor” 
awareness level.  
Among the participants attaining good scores, most were 
para-medical  workers  (n  =  3;  20%)  and  personnel  with 
experience of 4 to 6 years (n = 2; 28.6%). These associations 
were statistically significant. (Table 1) 
Three  (3.8%)  participants,  all  of  whom  were  students, 
indicated that they lacked faith in MDA by stating that it 
cannot effectively eliminate filariasis.  
 
Table 2. Association between occupation of participants 
and years of experience in MDA with their opinion as to 
whether MDA can be given to diabetic patients. 
 
Occupation  MDA  for 
DM 
patients 
MDA  not  for 
DM patients 
Total 
Students  54(93.1%)  4(6.9%)  58(100.0%) 
Para  medical 
workers 
13(86.7%)  2(13.3%)  15(100.0%) 
Non  medical 
workers 
1(20.0%)  4(80.0%)  5(100.0%) 
    χ2=22.014,DF=2,P<0.001 
Years  of 
experience  in 
MDA 
     
No 
experience 
54(88.5%)  7(11.5%)  61(100.0%) 
1  to  3  years 
of  experience 
in MDA 
8(80.0%)  2(20.0%)  10(100.0%) 
4  to  6  years 
of  experience 
in MDA 
6(85.7%)  1(14.3%)  7(100.0%) 
Total  68(87.2%)  10(12.8%)  78(100.0%) 
    χ2= 0.573,DF=2, P=0.751 
 
Each  participant  was  asked  about  the  responses  they 
received  from  people  when  they  delivered  the  drugs  to 
their  home.  They  reported  a  general  acceptance  of  the 
programme  with  few  queries.  Among  16  cases  in  which 
opposition to the programme was reported, eight of them 
reported that the people were fearful of fear of drug side 
effects. Other reasons stated by people for non-acceptance 
of  the  programme  were  an  unwillingness  to  take  tablets 
every year, the belief that the disease will not affect people 
belonging to the upper classes and presence of underlying 
diseases like hypertension and diabetes mellitus. 
Some of the participants in this study were found to hold 
misconceptions  regarding  groups  in  whom  MDA  is 
contraindicated. For instance 10 (12.8%) participants held 
the misconception that MDA should not be given to patients 
with DM and 7 (9.0%) believed that it should not be given to 
patients with hypertension. Also  7  (9.0%)  and  2  (2.6%) 
participants held the misconception that MDA should not 
be  given  to  elderly  (above  60  years)  and  “weak  people” 
respectively. 
The  misconception  that  MDA  tablets  cannot  be  given  to 
patients  with  diabetes  was  seen  significantly  more 
frequently  among  non-medical  workers  4(80%)  compared 
to others (χ2=22.014, P<0.001). (Table 2)  
The  misconception  that  MDA  tablets  cannot  be  given  to 
hypertensive  patients  was  again  seen  significantly  more 
frequently  among  non-medical  workers  3(60%)  compared 
to others (χ2=18.453, P<0.001). (Table 3) 
 
Table 3. Association between occupation of participants 
and experience in MDA with their opinion as to whether 
MDA can be given to hypertensive patients. 
 
Designation   MDA  for 
HTN 
patients 
MDA not for 
HTN patients 
Total 
Students  56(96.6%)  2(3.4%)  58(100.0%) 
Para  medical 
workers 
13(86.7%)  2(13.3%)  15(100.0%) 
Non  medical 
workers 
2(40.0%)  3(60.0%)  5(100.0%) 
    χ2=18.453,DF=2, P<0.001 
Years  of 
experience  in 
MDA 
     
No experience  57(93.4%)  4(6.6%)  61(100.0%) 
1 to 3 years of 
experience  in 
MDA 
8(80.0%)  2(20.0%)  10(100.0%) 
4 to 6 years of 
experience  in 
MDA 
6(85.7%)  1(14.3%)  7(100.0%) 
Total   71(91.0%)  7(9.0%)  78(100.0%) 
    χ2= 2.166, DF=2, P=0.339 
 
With regards to misconceptions that MDA drugs should not 
be  administered  to  patients  with  diabetes  and 
hypertension,  these  misconceptions  were  held  more 
commonly  among  participants  with  1  to  3  years  of 
experience  compared  to  those  with  4  to  6  years  of 
experience in this programme. (Table 2 &3) 
Four out of 15 (26.7%) paramedical workers felt that MDA 
was contraindicated in the elderly in comparison to 2 (3.4%) 
student participants and 1 (20%) non-medical worker.  Australasian Medical Journal AMJ 2011, 4, 2, 87-93. 
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(χ2=8.66, P=0.013). (Table 4) This misconception was found 
to  increase  with  years  of  experience  in  MDA  (χ2=  6.008, 
P=0.05). (Table 4) 
Seventeen  (21.8%)  participants  reported  that  MDA  was 
interfering  with  their  routine  work.  Thirteen  out  of  58  
nursing students (22.4%), reported this, 3 out of 15 (20%) 
paramedical  workers  and  1  out  of  5  (20%)  non-medical 
workers.   
Thirteen (21.3%) participants with no previous experience 
of the MDA, 2 (20.0%) with 1 to 3 years and 2 (28.6%) with 4 
to 6 years of experience in this programme felt that these 
postings did affect their routine work (χ2=0.216, P=0.898). 
 
Table 4. Association between occupation of participants 
and years of experience in MDA with opinion as to 
whether MDA can be given to elderly people. 
 
Designation   MDA  for 
elderly 
people 
MDA  not  for 
elderly people 
Total 
Students  56(96.6%)  2(3.4%)  58(100.0%) 
Para medical 
workers 
11(73.3%)  4(26.7%)  15(100.0%) 
Non  medical 
workers 
4(80.0%)  1(20.0%)  5(100.0%) 
    χ2=8.66, DF=2, P=0.013 
Years  of 
experience 
in MDA 
     
No 
experience 
58(95.1%)  3(4.9%)  61(100.0%) 
1  to  3  years 
of 
experience 
in MDA 
8(80.0%)  2(20.0%)  10(100.0%) 
4  to  6  years 
of 
experience 
in MDA 
5(71.4%)  2(28.6%)  7(100.0%) 
Total   71(91.0%)  7(9.0%)  78(100.0%) 
    χ2= 6.008, DF=2, P=0.05 
 
Common  suggestions  given  by  participants  for  improving 
the MDA programme for future rounds were to improve the 
training for the personnel delivering the programme (n = 8; 
10.3%) and to provide a more detailed explanation about 
the disease to patients (n = 8; 10.3%). (Table 5) 
 
Table 5. Suggestions given by participants for improving 
MDA programme (n=78). 
 
Suggestions  No. (%) 
Training should be more extensive  8(10.3) 
Explanation of disease should be more in 
detail 
8(10.3) 
Increase awareness level of people   7(9.0) 
Canvassing  can  be  improved  by  targeting 
schools & public places  
2(2.6) 
Increase the honorarium of volunteers   1(1.3) 
Increase manpower in MDA programme  1(1.3) 
Discussion 
Elimination  of  lymphatic  filariasis  by  2015  requires 
treatment coverage of the MDA programme of at least 80% 
in high risk areas. However, the drug consumption rate has 
been found to be unsatisfactory, even in the most literate of 
districts, during previous rounds of MDA held in Karnataka 
state.
 [6] Possible explanations could include that the target 
population are either ill informed or are not fully convinced 
about  the  usefulness  of  this  programme.
[5]  In  these 
circumstances the level of knowledge and communication 
skills  of  personnel  who  deliver  the  drugs  may  be  an 
important  factor  that  determines  compliance  with  the 
programme and thus the success of MDA .
[7] 
Udupi  district  with  the  highest  literacy  rate  (92%)  in 
Karnataka  state  has  not  demonstrated  good  rates  of 
compliance for MDA over the years.
 [6, 8] Coverage could be 
worse still in less literate districts of India. 
This study showed that only four (5.1%) of the participants 
posted for drug distribution had a good knowledge about 
MDA.  Interestingly  this  was  better  than  the  findings  of a 
study done in few districts of Kerala during the November 
2005 MDA round in which no paramedical personnel had a  
good knowledge. 
[5] From this it is obvious that the drug 
deliverers  were  not  adequately  aware  about  LF  and  the 
MDA  programme  and  this  could  affect  compliance  rate 
among people as these personnel are not in a position to 
clear all their doubts.  
For any programme to be successful in the community, the 
target  population  need  to  be  fully  educated  about  all 
aspects  of  it  to  alleviate  apprehensions.  For  this  it  is 
essential that the personnel who are supposed to educate 
the community should have the required knowledge about 
the programme. Lack of knowledge among health personnel 
may lead to failure to clear the doubts of the community 
and it may potentially instill suspicion about the programme 
thus, potentially, fuelling rumours spread by individuals who 
are opposed to the programme. 
[5] 
Most participants had no prior experience in MDA before 
being  posted  in  this  round.  Performance  scores  were 
significantly  poorer  among  the  inexperienced  participants 
and non-medical workers in our study. Thus trainers need to 
focus more on these groups during training sessions. 
Only a few participants in our study felt that MDA will not 
help in LF elimination. This was in contrast to the findings of 
a study done in Orissa in which 76% of medical personnel 
felt that the elimination is not feasible through MDA.
[9] It is 
unfortunate  that  even  after  many  years  of  programme 
implementation, a few volunteers who are working for the 
programme  do  not  have  faith  in  it.  Such  indifferent 
attitudes among them might arise from lack of knowledge 
or  erroneous  beliefs.    When  they  themselves  are  not 
convinced of the benefit of the programme they may not be 
able  to  effectively  communicate  the  benefits  of  the 
programme to the community. Therefore they need to be 
better  educated  about  the  benefits  and  success  of  this 
programme during training sessions before the MDA rounds 
commence. 
Common reasons of non compliance as told by participants 
were  similar  to  findings  from  other  studies  which  also 
quoted  a  fear  of  the  side-effects  of  the  drugs  used,  “no  Australasian Medical Journal AMJ 2011, 4, 2, 87-93. 
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disease so not necessary” and ignorance as major factors. 
[4, 
6, 10] 
In a study by Kumar et al it was observed that only 16.7% 
medicine distributors explained about safety or the possible 
side-effects  of  medicine.
  [6]  Therefore,  the  role  of  the 
personnel involved in the MDA is mostly restricted to tablet 
distribution only and their roles as educators in major issues 
such  as drug compliance, health education, side effect and 
morbidity management were not being given due attention.  
For the successful implementation of the MDA programme 
proper planning, intense and timely efforts to motivate the 
community  and  innovative  drug  delivery  strategies  are 
required.  
Misconceptions  such  as  MDA  being  contraindicated  in 
hypertensive  and  diabetic  patients  were  present  in  some 
personnel.  This  proportion  was  significantly  more  among 
non-medical  workers.  However  it  was  interesting  to  note 
that a much higher proportion of paramedical workers had 
this  misconception  than  the  students.  Relative  lack  of 
proper  knowledge  among  paramedical  workers  highlights 
the need to dispel their misconceptions. This is vital as they 
will continue to be in the health sector and therefore will 
have  at  least  an  indirect  impact  on  the  programme  as  a 
whole.  This  is  further  evidenced  by  the  fact  that  the 
misconception  that  the  elderly  were  not  to  be  given  the 
tablets was highest among the paramedical workers. This 
misconception  also  prevailed  more  among  the  ones  who 
were most experienced in the field as compared to the ones 
who  were  new  to  the  programme.  These  observations 
highlight the areas where training needs to be emphasized 
upon in future rounds. 
More than one fifth of participants stated that postings in 
MDA were interfering with their usual activities. This could 
mean that some of our personnel may not be sufficiently 
motivated to take up this important public health initiative. 
So in future rounds care has to be taken in selecting only 
highly motivated participants. 
Only a small number of the participants chose to give any 
suggestions for programme improvement and of the ones 
who did, most felt that training had to be more extensive 
and the disease had to be dealt with in more detail. Another 
common  suggestion  was  to  increase  awareness  through 
improvement in information education and communication 
(IEC)  activities.  A  few  participants  pointed  out  that  the 
numbers of field personnel posted during MDA rounds are 
usually inadequate hence the government authorities need 
to increase the manpower. Also they complained that the 
honorarium given to them was too little and did not reflect 
the  work  involved  in  going  house-to-house  to  distribute 
these tablets during MDA rounds.  
This  study  has  therefore  highlighted  areas  in  which  MDA 
programme  administrators  need  to  work  to  improve  the 
programme efficiency and to eliminate LF by 2015. 
 
Conclusion 
Most participants in the study were posted for the first time 
in  MDA  activity  and  majority  of  them  were  students. 
Overall, knowledge of the participants was lacking in many 
aspects and this was reflected by their poor score in the 
study questionnaire and detection of misconceptions held. 
The wrong notion that the drug should not be administered 
to the diabetics, hypertensives and elderly were prevalent 
among all types of workers. More alarming was its presence 
among the paramedical personnel. Some of the participants 
seemed to find the posting an inconvenience, however most 
appeared to have faith in the programme’s effectiveness to 
eliminate  LF,  which  is  good  for  the  programme.  These 
findings, and the suggestions for improvement provided by 
the participants, highlight the need to incorporate certain 
changes in the programme to improve efficiency especially 
in terms of better training not only for new workers but also 
experienced  and  health  care  staff.  These  measures  will 
equip  the  personnel  to  be  more  efficient  in  clearing  the 
doubts  of  the  general  public  and  may  promote 
commitment,  involvement  and  motivation  of  the  target 
population  thus  potentially  enhancing  levels  of  drug 
consumption.  
If other identified technical and administrative constraints 
are also addressed in an effective way, the elimination of LF 
can be made a reality, possibly even before the stipulated 
time of 2015. 
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Questionnaire 
1.  Designation ………………. 
2.  Gender …………….. 
3.  Age ……….. 
4.  Years of service ………… 
5.  Years of experience in MDA against filariasis 
…………. 
6.  What causes filariasis ……………….. 
7.  What transmits filariasis from one person to 
another ……………… 
8.  What are the clinical features of filariasis 
…………………………………… 
9.  How to diagnose filariasis in laboratory…………… 
Time of testing ………………….. 
10.  What are the drugs given in MDA Drug 1 
………………… and Drug 2 …………………….. 
11.  Strength of 1
st drug ………… mg.  Dosage in various 
age groups ………….., …………………, …………………. 
12.  Strength of 2
nd drug …………… mg. Dosage 
……………… 
13.  What are the side effects of 1
st drug 
…………………………………………………………………… 
14.  What are the side effects of 2
nd drug 
………………………………………… 
15.  Who should not take these tablets 
…………………………………………………………… 
16.  Why do we give these tablets 
…………………………………………………….. 
17.  By which year is Government planning to eliminate 
filariasis …………………. 
18.  When will be the next round of MDA ……………. 
19.  Totally how many rounds of MDA will be 
conducted ………………….. 
20.  What should be the minimum percentage of 
population coverage during MDA rounds ………….% 
21.  Do you think MDA will be effective in eliminating 
filariasis   yes/no 
22.  Does postings in MDA activity affect your other 
routine daily activities  yes/no 
23.  What are the common responses of people to 
whom you gave drugs 
a.  …………………………………………………………………. 
b.  …………………................................................. 
c.  …………………………………………………………………. 
d.  …………………………………………………………………. 
24.  Reasons stated by people for not accepting MDA 
a.  …………………………………………………………………. 
b.  …………………………………………………………………. 
c.  …………………………………………………………………. 
d.  …………………………………………………………………. 
25.  Any suggestions for improving this programme 
 
 
Answers to the study questionnaire and 
scoring system 
6. Filarial worm (3 marks) 
7. Mosquitoes (3 marks) 
8. Fever, lymph node enlargement, elephantiasis, 
hydrocele (1x4=4 marks) 
9. Blood smear, night (3+3=6 marks) 
10. Drug 1: Diethylcarbamazine (DEC), Drug 2: 
Albendazole  (5+5=10 marks) 
11. 100 mg, 2 to 5 years – 1 tablet, 6 to 14 years – 2 
tablets, above 14 years – 3 tablets (3+7+7+7=24 
marks) 
12. 400 mg, above 2 years onwards – 1 tablet 
(3+7=10 marks) 
13. Headache, nausea, anorexia, weight loss, skin 
rashes, dizziness (1X6=6 marks) 
14. Headache, nausea, dizziness, fever, hair loss, 
stomach pain, diarrhoea, skin rashes (1X8 = 8 
marks) 
15. Children below 2 years, pregnant women, 
chronically sick persons (3X5=15 marks) 
16. Elimination of filariasis (3 marks) 
17. 2015 (2 marks) 
18. Next year (2 marks) 
19. 5 to 7 rounds (2 marks) 
20. 80% (2 marks) 
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Scores 
Maximum marks: 100 
Must know questions no. 10, 11, 12, 13 (at least 2 
side effects), 14 (at least 2 side effects), 15, 16 
which total to 60 marks 
Marks less than or equal to 60 is poor performance 
Nice to know questions no. 17, 18, 19, 20, 13 (more 
than 3 side effects), 14 (more than 4 side effects) 
which totals to 15 marks 
Marks between 85 (15 marks deducted from 
maximum possible marks) to 100 is good 
performance 
Desirable to know questions : Rest questions  
Marks between 61 to 84 is for satisfactory or 
average performance 
 